Yongquan Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongquan Huang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Bojian Chen
Guangzhou Univ Tradit Chinese Med, Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou 510 0 06, Peoples R China
1 shared publication Dongfeng Chen
Department of Anatomy, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China
1 shared publication- Fangzheng Lin
Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication Haitao Su
Department of Orthopaedics, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China
1 shared publication- Haitao Su
The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
1 shared publication - Haizhou Wang
Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, China
1 shared publication
Latest Publications
- Open Access
- 23 August 2019
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 20 (4) , 3746-3754
miR‑488 negatively regulates osteogenic differentiation of bone marrow mesenchymal stem cells induced by psoralen by targeting Runx2
It has been previously reported that psoralen, one of the active ingredients in Psoralea corylifolia, could induce osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), suggesting its potential to treat osteoporosis. Additionally, runt‑related transcription factor 2 (Runx2) is a transcription factor that plays vital roles in BMSC osteogenic differentiation. However, whether and how microRNAs (miRNAs/miRs) modulate osteogenic differentiation induced by psoralen have not yet been examined, to the best of the authors' knowledge. The present study aimed to identify the miRNA target genes that regulate osteogenic differentiation of BMSCs induced by psoralen. A Cell Counting Kit‑8 assay and alizarin red staining were used to detect the viability and osteogenic differentiation of BMSCs, respectively, under treatment with psoralen. miRNA microarray analysis was performed to identify the differentially expressed miRNAs under treatment with psoralen. A bioinformatics analysis and a luciferase reporter assay were conducted to identify the targets of miR‑488. Finally, the mechanisms of miR‑488 in psoralen‑induced BMSC osteogenic differentiation were investigated using overexpression or inhibition methods in vitro. Cell viability was elevated and osteogenic differentiation of BMSCs was improved under treatment with psoralen. miRNA microarray analysis and further validation by reverse transcription‑quantitative PCR revealed that miR‑488 was downregulated during psoralen‑induced BMSC osteogenic differentiation. Bioinformatics analysis and experimental validation by a luciferase reporter assay identified Runx2 as a potential target of miR‑488. Overexpression of miR‑488 by transfection with miR‑488 mimics markedly inhibited the expression of Runx2, Osterix and alkaline phosphatase, whereas, the inhibition of miR‑488 expression by the miR‑488 inhibitor promoted their expression compared with the control. Rescue assays demonstrated that Runx2 overexpression partially rescued the inhibitory effect of miR‑488 on BMSC osteogenic differentiation. The present results suggested that miR‑488 is a negative regulator of psoralen‑induced BMSC osteogenic differentiation by targeting Runx2, providing a possible therapeutic target for osteoporosis.
- 23 August 2019
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 20 (4) , 3746-3754
Open AccessmiR‑488 negatively regulates osteogenic differentiation of bone marrow mesenchymal stem cells induced by psoralen by targeting Runx2
It has been previously reported that psoralen, one of the active ingredients in Psoralea corylifolia, could induce osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), suggesting its potential to treat osteoporosis. Additionally, runt‑related transcription factor 2 (Runx2) is a transcription factor that plays vital roles in BMSC osteogenic differentiation. However, whether and how microRNAs (miRNAs/miRs) modulate osteogenic differentiation induced by psoralen have not yet been examined, to the best of the authors' knowledge. The present study aimed to identify the miRNA target genes that regulate osteogenic differentiation of BMSCs induced by psoralen. A Cell Counting Kit‑8 assay and alizarin red staining were used to detect the viability and osteogenic differentiation of BMSCs, respectively, under treatment with psoralen. miRNA microarray analysis was performed to identify the differentially expressed miRNAs under treatment with psoralen. A bioinformatics analysis and a luciferase reporter assay were conducted to identify the targets of miR‑488. Finally, the mechanisms of miR‑488 in psoralen‑induced BMSC osteogenic differentiation were investigated using overexpression or inhibition methods in vitro. Cell viability was elevated and osteogenic differentiation of BMSCs was improved under treatment with psoralen. miRNA microarray analysis and further validation by reverse transcription‑quantitative PCR revealed that miR‑488 was downregulated during psoralen‑induced BMSC osteogenic differentiation. Bioinformatics analysis and experimental validation by a luciferase reporter assay identified Runx2 as a potential target of miR‑488. Overexpression of miR‑488 by transfection with miR‑488 mimics markedly inhibited the expression of Runx2, Osterix and alkaline phosphatase, whereas, the inhibition of miR‑488 expression by the miR‑488 inhibitor promoted their expression compared with the control. Rescue assays demonstrated that Runx2 overexpression partially rescued the inhibitory effect of miR‑488 on BMSC osteogenic differentiation. The present results suggested that miR‑488 is a negative regulator of psoralen‑induced BMSC osteogenic differentiation by targeting Runx2, providing a possible therapeutic target for osteoporosis.